PBI-4050 is an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in several in vivo experiments targeting fibrosis. Fibrosis is a very complex process by which continuing inflammation causes vital organs to lose their function as normal tissue is replaced by fibrotic scar tissue. The proof of concept data generated to date confirms our lead drug candidates’ anti-fibrotic activity in several key organs including the kidneys, the heart, the lungs and the liver.
Currently, indications being pursued for PBI-4050 include Idiopathic Pulmonary Fibrosis (IPF), Alström syndrome, Liver Fibrosis (NASH) and Chronic Kidney Diseases (CKD)/Diabetic Kidney Diseases.
You can find more information on each of these indications below.